EXANE DERIVATIVES - NOVOCURE LTD ownership

NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 318 filers reported holding NOVOCURE LTD in Q2 2022. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of NOVOCURE LTD
ValueSharesWeighting
Q2 2022$208,000
-99.7%
3
-99.6%
0.00%
-100.0%
Q1 2022$65,365,000
-8.4%
789
-16.9%
0.02%
+5.9%
Q4 2021$71,323,000
-50.2%
950
-23.0%
0.02%
-50.0%
Q3 2021$143,349,000
-47.1%
1,234
-14.2%
0.03%
-44.3%
Q2 2021$271,028,000
+8.5%
1,438
-23.9%
0.06%
-14.1%
Q1 2021$249,811,000
-46.7%
1,890
-30.2%
0.07%
-48.6%
Q4 2020$468,747,0002,7090.14%
Other shareholders
NOVOCURE LTD shareholders Q2 2022
NameSharesValueWeighting ↓
Invus Financial Advisors, LLC 350,884$26,344,0008.01%
HARTLINE INVESTMENT CORP/ 318,109$23,884,0003.27%
Deep Track Capital, LP 550,000$41,294,0002.92%
MORGAN JESS S & CO INC 43,975$3,302,0002.03%
Taylor Frigon Capital Management LLC 46,376$3,482,0001.09%
Darsana Capital Partners LP 258,937$19,441,0000.90%
Private Harbour Investment Management & Counsel, LLC 13,562$1,018,0000.81%
Rhenman & Partners Asset Management AB 120,387$9,610,0000.64%
COURAGE CAPITAL MANAGEMENT LLC 10,000$751,0000.50%
Baillie Gifford 9,615,168$721,906,0000.40%
View complete list of NOVOCURE LTD shareholders